Anticancer agent 300
Anticancer agent 300 (compound P14) is a CCND1, CDK4, CDK6, and CCNE1 modulator, with anti-proliferative, cell-cycle modulatory, senescence-inducing, and apoptosis-inducing activity. Anticancer agent 300 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.
For research use only. We do not sell to patients.
- CAS No.: 1310059-06-3
- Formula: C24H19N3OS2
- Molecular Weight:429.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Anticancer agent 300 (P14) (5-50 μM; 7 days) significantly reduces colony-forming capacity in MCF7 and A375 cells and induces cytotoxicity in non-tumoral TC28a2 cells at high concentrations[1].
Anticancer agent 300 (P14) (5-50 μM; 7 days) has an IC50 of 2.018 μM in MCF7 cells and 1.887 μM in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 12 days) significantly reduces spheroid area in MCF7 and A375 3D cultures[1].
Anticancer agent 300 (P14) (5 μM; 7 days) reduces the proportion of G2/M phase cells in MCF7 and A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) modulates the expression of cell-cycle-related genes in a cell-type-specific manner, upregulating G1/S transition genes in MCF7 cells and downregulating them in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) increases the expression of senescence-associated genes in MCF7 and A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) upregulates SASP factors in MCF7 cells and reduces their synthesis in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) increases cell death and early apoptosis in MCF7 and A375 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF7, A375, TC28a2
-
Concentration:5, 20, 35, 50 μM
-
Incubation Time:7 days
-
Result:Significantly reduced the colony-forming capacity of MCF7 and A375 cells in a dose-dependent manner. Demonstrated potent anti-proliferative effects even at 5 μM in both cell lines.
Induced cytotoxicity in non-tumoral TC28a2 cells at high concentrations (up to 20 μM).
-
Cell Line:MCF7, A375
-
Concentration:5, 20, 35, 50 μM
-
Incubation Time:7 days
-
Result:Achieved an IC50 of 2.018 μM in MCF7 cells and 1.887 μM in A375 cells.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:12 days
-
Result:Significantly reduced spheroid area in MCF7 cells after 8 and 12 days of treatment, and in A375 cells with a less marked but still statistically significant reduction.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:7 days
-
Result:Reduced the proportion of cells in the G2 phase in both cell lines: decreased MCF7 cells' G2/M phase proportion from 26.25% (control) to 13.10%, and A375 cells' G2/M phase proportion from 5.44% (control) to 0.52%.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:7 days
-
Result:Significantly upregulated genes associated with G1/S transition and S-phase entry in MCF7 cells.
Significantly downregulated key regulators of the G1/S transition and S-phase entry, including CCND1, CDK4, CDK6, and CCNE1, in A375 cells.
Notably increased the expression of senescence-associated factors, including p21, p53, and p53-responsive genes (IGFBP3 and GDF15), in both cell lines.
Significantly upregulated classical SASP components, including IL-6 and IL-8, in MCF7 cells.
Showed a trend toward reduced synthesis of SASP factors in A375 cells.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:7 days
-
Result:Showed a tendency to increase cell death and the proportion of cells undergoing early apoptosis in both cell lines.
Chemical Information
-
CAS No. 1310059-06-3
-
Molecular Weight 429.56
-
Formula C24H19N3OS2
-
SMILES
C12=C(SC(C3=CC(C4=CC5=C(S4)C=CC=C5)=NC(N6CCOCC6)=N3)=C2)C=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)